Noell Claire, Arbeit Robert, Kanhoush Rima
Department of Dermatology, Tufts Medical Center, Boston, Massachusetts.
Dermatol Online J. 2018 Jan 15;24(1):13030/qt3v77g2zg.
Tofacitinib is a targeted inhibitor of janus kinase (JAK), currently approved for the treatment of rheumatoid arthritis. We present a patient on treatment withtofacitinib who had an episode of classic dermatomal herpes zoster followed months later by atypical chronic cutaneous ulcers also caused by herpes zoster.
托法替布是一种Janus激酶（JAK）靶向抑制剂，目前已被批准用于治疗类风湿性关节炎。我们报告了一名正在接受托法替布治疗的患者，该患者曾发生一次典型的皮节带状疱疹，数月后又出现了同样由带状疱疹引起的非典型慢性皮肤溃疡。
